Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

HIV is a lifelong infection that affects many people. People with HIV take many different types of medicines to help control their condition and to prevent the infection from developing into AIDS.

Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...